Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 7 | -$0.33 | -$0.06 | -$0.21 |
Q2 2025 | 3 | -$0.28 | -$0.21 | -$0.23 |
Q3 2025 | 6 | -$0.33 | -$0.25 | -$0.27 |
Q4 2025 | 5 | -$0.41 | -$0.31 | -$0.34 |
Q1 2026 | 4 | -$0.09 | -$0.07 | -$0.07 |
Q2 2026 | 3 | -$0.12 | -$0.09 | -$0.10 |
Q3 2026 | 2 | -$0.15 | -$0.12 | -$0.13 |
Q4 2026 | 2 | -$0.19 | -$0.14 | -$0.16 |
Immunocore Holdings plc last posted its earnings results on Wednesday, November 6th, 2024. The company reported $0.17 earnings per share for the quarter, topping analysts' consensus estimates of $-0.35 by $0.52. The company had revenue of 80.25 M for the quarter and had revenue of 249.43 M for the year. Immunocore Holdings plc has generated $-1 earnings per share over the last year ($-1.13 diluted earnings per share) and currently has a price-to-earnings ratio of -27.91. Immunocore Holdings plc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/06/2024 | Q3 2024 | -$0.35 | $0.17 | 0.52 | $78.94 M | $80.25 M |
08/08/2024 | Q2 2024 | -$0.45 | -$0.23 | 0.22 | $74.58 M | $75.40 M |
05/08/2024 | Q1 2024 | -$0.33 | -$0.49 | -0.16 | $70.50 M | |
02/28/2024 | Q4 2023 | -$0.28 | -$0.54 | -0.26 | $105.64 M | |
11/07/2023 | Q3 2023 | -$0.32 | $0.05 | 0.37 | $62.79 M | $62.62 M |
05/10/2023 | Q2 2023 | -$0.30 | -$0.37 | -0.07 | $57.76 M | $60.48 M |
03/01/2023 | Q1 2023 | -$0.00 | -$0.43 | -0.43 | $55.06 M | |
11/09/2022 | Q4 2022 | -$0.26 | -$0.54 | -0.28 | $48.06 M | |
08/10/2022 | Q3 2022 | -$0.72 | $0.13 | 0.85 | $37.39 M | $41.20 M |
05/11/2022 | Q2 2022 | -$1.07 | -$0.14 | 0.93 | $20.97 M | $32.00 M |
03/03/2022 | Q1 2022 | -$1.08 | -$0.37 | 0.71 | $22.47 M | |
11/10/2021 | Q4 2021 | -$0.85 | -$0.90 | -0.05 | $6.59 M | |
08/11/2021 | Q3 2021 | -$0.95 | -$0.69 | 0.26 | $7.36 M | $5.92 M |
05/12/2021 | Q2 2021 | -$0.83 | -$0.75 | 0.08 | $7.83 M | $5.73 M |
05/12/2021 | Q1 2021 | -$0.83 | -$0.76 | 0.07 | $8.27 M | |
03/25/2021 | Q4 2020 | -$1.05 | -$0.49 | 0.56 | $7.42 M | |
09/29/2020 | Q3 2020 | -$0.61 | $6.65 M | |||
06/29/2020 | Q2 2020 | -$0.63 | $7.79 M | |||
03/30/2020 | Q1 2020 | -$0.68 | $8.26 M | |||
12/30/2019 | Q4 2019 | -$0.95 | $5.64 M |
Immunocore Holdings plc has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
In the previous quarter, Immunocore Holdings plc (:IMCR) reported $0.17 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.35 by $0.52.
The conference call for Immunocore Holdings plc's latest earnings report can be listened to online.
The conference call transcript for Immunocore Holdings plc's latest earnings report can be read online.
Immunocore Holdings plc (:IMCR) has a recorded annual revenue of $249.43 M.
Immunocore Holdings plc (:IMCR) has a recorded net income of $249.43 M. Immunocore Holdings plc has generated $-1.13 earnings per share over the last four quarters.
Immunocore Holdings plc (:IMCR) has a price-to-earnings ratio of -27.91 and price/earnings-to-growth ratio is -2.81.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED